Presumed Passive Immune Thrombocytopaenia in twin infants, secondary to Maternal Autoimmune Disease. A Case Report.

Main Article Content

Onumaku .I. J.
Ekeh U
Nte .A. R
Okite .P. U.

Abstract

Background:
Passive immune thrombocytopaenia (PIT)in infants results following transfer of maternal anti-platelet antibodies trans-placentally or via breastmilk particularly in mothers with autoimmune disorders.

Objectives.
This report aims to highlight the possibility of occurrence of PIT beyond the neonatal period and the treatment strategies employed.

Case Presentation:
A set of 4-month-old female twins presented with recurrent melaena, nasal and gingival bleeds of 2 months duration, fever of 2 weeks and tachypnoea and generalised weakness of 2 days duration. Both infants were severely pale and laboratory evaluation revealed profound thrombocytopaenia (14 x109 /l and 8 x 109/L respectively) and severe anaemia. Their mother had severe anaemia in the third trimester of pregnancy requiring repeated blood transfusions and following admission of the twins, was further evaluated and a diagnosis of Systemic Lupus Erythematosus made. The twins received fresh whole-blood transfusions, initial treatment with intravenous methylprednisolone with no improvement and subsequently received Intravenous Immunoglobulin which led to a rapid rise in platelet counts and resolution of bleeding.

Discussion:
The effect of maternal anti-platelet antibodies in the baby may persist beyond the neonatal period even up till 4 months of age, as in this report. Despite paucity of literature on this as a cause of immune thrombocytopaenia in infants, a high index of suspicion should be maintained.

Conclusion:
Persistent, severe or unexplained thrombocytopaenia in an infant should prompt careful review of maternal autoimmune status if previously unknown and antiplatelet antibody investigations. Intravenous Immunoglobulin is very effective in treatment of steroid-refractory passive immune thrombocytopaenia.
Views: 0Downloads: 0

Downloads

Download data is not yet available.

Article Details

Section

Articles

How to Cite

Presumed Passive Immune Thrombocytopaenia in twin infants, secondary to Maternal Autoimmune Disease. A Case Report. (2026). International Journal Of Basic And Clinical Sciences, 1(1), 1-9. https://doi.org/10.83161/ijbacs.vol1no1.5

References

1. Stephen HL, Stephen AH. NELSON TEXTBOOK OF PAEDIATRICS 20th EDITION. 20th ed. Vol. 2. Canada: Elsevier; 2016. 2400–2404 p.

2. Sillers L, Van Slambrouck C, Lapping-Carr G. Neonatal Thrombocytopaenia: Etiology and Diagnosis. Pediatr Ann. 2015;44(7). e175-180.

3. Lee A. Isolated thrombocytopaenia in childhood: what if it is not immune thrombocytopaenia?. Singapore Medical Journal. 2018;59(7):390–3.

4. Grace RF, Lambert MP. An update on pediatric ITP: differentiating primary ITP, IPD, and PID.

Blood. 2022;140(6):542-555.

doi:10.1182/blood.2020006480.

5. Lee AC wai. Immune thrombocytopaenia in infants: a retrospective study with comparison to toddlers. Singapore Medical Journal. 2025;66(1):20–3.j.SMJ-2021-184

6. Pietras NM, Gupta N, Justiz Vaillant AA, Pearson-Shaver AL. Immune Thrombocytopaenia. 2024.

7. Batton E, Leibel SL. Immune-mediated neonatal thrombocytopaenia. NeoReviews.

2022;23(7):e462-e471. doi:10.1542/neo.23-7-e462.

8. Kaplan C. Immune thrombocytopaenia in the foetus and the newborn: diagnosis and therapy. Transfus Clin Biol. 2001;8(3):311-314. doi:10.1016/S1246-7820(01)00114-8.

9. Hauschner H, Rosenberg N, Seligsohn U, Mendelsohn R, Simmonds A, Shiff Y, et al. Persistent neonatal thrombocytopaenia can be caused by IgA antiplatelet antibodies in breast milk of immune thrombocytopaenic mothers. Blood . 2015;126(5):661–4. doi:10.1182/blood-2014-12-614446.

10. Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopaenia. Blood Adv. 2019;3(22):3780-3817.

11. Shaikh H, Mewawalla P. Evans Syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Available from: http://www.ncbi.nlm.nih.gov/books/NBK519015/

12. Kim TO, Despotovic JM. Pediatric immune thrombocytopaenia (ITP) treatment. Annals of Blood. 2021;6(0).

13. Schmidt D.E,Heitink-Polle M.J.K, Bruin C.A.M, Haas de M. Intravenous Immunoglobulins (IVIg) in

childhood immune thrombocytopaenia: towards personalised medicine-a narrative review. Vol 6.

2021. doi:10.21037/aob-20-59

Similar Articles

You may also start an advanced similarity search for this article.